Novel Small-Molecule Drug Candidate for Oncology

**OCR Number:** OCR 1642

**Description:**

- GFB-204 is a novel compound that binds PDGF and VEGF and prevents binding to their respective receptors, and subsequently suppresses downstream signaling pathways.
- GFB-204 is selective for PDGF and VEGF, and does not inhibit EGF, IGF-1 and FGF stimulation of Erk1/2, Akt, and STAT3.
- As shown in the figure, GFB-204 causes a marked decrease in tumor volume in a mouse xenograft model.
- Inhibition of VEGF and PDGF receptor binding with GFB-204 results in potent inhibition of angiogenesis and tumorigenesis.
- IND-enabling studies have been initiated for GFB-204 for AMD and cancer.

Published/Issued Patents: [U.S. Patent No. 7,482,483](https://www.google.com/search?q=U.S.+Patent+No.+7,482,483),


Publications:

Licensing Contact: John Puziss
john.puziss@yale.edu